Search

Your search keyword '"Chabot-Blanchet, Malorie"' showing total 20 results
Start Over Author "Chabot-Blanchet, Malorie" Publication Year Range Last 50 years
20 results on '"Chabot-Blanchet, Malorie"'

1. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Author

Tardif, Jean-Claude, Bouabdallaoui, Nadia, L'Allier, Philippe L, Gaudet, Daniel, Shah, Binita, Pillinger, Michael H, Lopez-Sendon, Jose, da Luz, Protasio, Verret, Lucie, Audet, Sylvia, Dupuis, Jocelyn, Denault, André, Pelletier, Martin, Tessier, Philippe A, Samson, Sarah, Fortin, Denis, Tardif, Jean-Daniel, Busseuil, David, Goulet, Elisabeth, Lacoste, Chantal, Dubois, Anick, Joshi, Avni Y, Waters, David D, Hsue, Priscilla, Lepor, Norman E, Lesage, Frédéric, Sainturet, Nicolas, Roy-Clavel, Eve, Bassevitch, Zohar, Orfanos, Andreas, Stamatescu, Gabriela, Grégoire, Jean C, Busque, Lambert, Lavallée, Christian, Hétu, Pierre-Olivier, Paquette, Jean-Sébastien, Deftereos, Spyridon G, Levesque, Sylvie, Cossette, Mariève, Nozza, Anna, Chabot-Blanchet, Malorie, Dubé, Marie-Pierre, Guertin, Marie-Claude, and Boivin, Guy

Published
2021
Full Text
View/download PDF

2. Genetics of symptom remission in outpatients with COVID-19

Author

Dubé, Marie-Pierre, Lemaçon, Audrey, Barhdadi, Amina, Lemieux Perreault, Louis-Philippe, Oussaïd, Essaïd, Asselin, Géraldine, Provost, Sylvie, Sun, Maxine, Sandoval, Johanna, Legault, Marc-André, Mongrain, Ian, Dubois, Anick, Valois, Diane, Dedelis, Emma, Lousky, Jennifer, Choi, Julie, Goulet, Elisabeth, Savard, Christiane, Chicoine, Lea-Mei, Cossette, Mariève, Chabot-Blanchet, Malorie, Guertin, Marie-Claude, de Denus, Simon, Bouabdallaoui, Nadia, Marchand, Richard, Bassevitch, Zohar, Nozza, Anna, Gaudet, Daniel, L’Allier, Philippe L., Hussin, Julie, Boivin, Guy, Busseuil, David, and Tardif, Jean-Claude

Published
2021
Full Text
View/download PDF

4. A disease-specific comorbidity index for predicting mortality in patients admitted to hospital with a cardiac condition

Author

Azzalini, Lorenzo, Chabot-Blanchet, Malorie, Southern, Danielle A., Nozza, Anna, Wilton, Stephen B., Graham, Michelle M., Gravel, Guillaume Marquis, Bluteau, Jean-Pierre, Rouleau, Jean-Lucien, Guertin, Marie-Claude, and Jolicoeur, E. Marc

Subjects
Coronary heart disease -- Prognosis -- Patient outcomes -- Comparative analysis -- Health aspects, Comorbidity -- Prognosis -- Patient outcomes -- Comparative analysis -- Analysis, Mortality -- Analysis -- Quebec, Novels, Cardiology, Regression analysis, Medical research, Health
Abstract

BACKGROUND: Comorbidity indexes derived from administrative databases are essential tools of research in global health. We sought to develop and validate a novel cardiac-specific comorbidity index, and to compare its accuracy with the generic Charlson-Deyo and Elixhauser comorbidity indexes. METHODS: We derived the cardiac-specific comorbidity index from consecutive patients who were admitted to hospital at a tertiary-care cardiology hospital in Quebec. We used logistic regression analysis and incorporated age, sex and 22 clinically relevant comorbidities to build the index. We compared the cardiac-specific comorbidity index with refitted Charlson-Deyo and Elixhauser comorbidity indexes using the C-statistic and net reclassification improvement to predict in-hospital death, and the Akaike information criterion to predict length of stay. We validated our findings externally in an independent cohort obtained from a provincial registry of coronary disease in Alberta. RESULTS: The novel cardiac-specific comorbidity index outperformed the refitted generic Charlson-Deyo and Elixhauser comorbidity indexes for predicting in-hospital mortality in the derivation population (n = 10 137): C-statistic 0.95 (95% confidence interval [CI] 0.94-0.9) v. 0.81 (95% CI 0.77-0.84) and 0.86 (95% CI 0.82-0.89), respectively. In the validation population (n = 17877), the cardiac-specific comorbidity index was similarly better: C-statistic 0.92 (95% CI 0.89-0.94) v. 0.76 (95% CI 0.71-0.81) and 0.82 (95% CI 0.78-0.86), respectively, and also numerically outperformed the Charlson-Deyo and Elixhauser comorbidity indexes for predicting 1-year mortality (C-statistic 0.78 [95% CI 0.76-0.80] v. 0.75 [95% CI 0.73-0.77] and 0.77 [95% CI 0.75-0.79], respectively). Similarly, the cardiac-specific comorbidity index showed better fit for the prediction of length of stay. The net reclassification improvement using the cardiac-specific comorbidity index for the prediction of death was 0.290 compared with the Charlson-Deyo comorbidity index and 0.192 compared with the Elixhauser comorbidity index. INTERPRETATION: The cardiac-specific comorbidity index predicted in-hospital and 1-year death and length of stay in cardiovascular populations better than existing generic models. This novel index may be useful for research of cardiology outcomes performed with large administrative databases., The processing of large health administrative data sets has been facilitated by the implementation of national comprehensive registries. Successful examples of outcomes research based on these data include randomized trials [...]

Published
2019
Full Text
View/download PDF

5. PO-02-106 GENERAL ANESTHESIA VERSUS CONSCIOUS SEDATION WITH LOCOREGIONAL ANESTHESIA IN S-ICD IMPLANTATION: A MONOCENTRIC RETROSPECTIVE ANALYSIS

Author

De Marco, Corrado, primary, Lebon, Jean-Sébastien, additional, Rousseau-Saine, Nicolas, additional, Dubuc, Marc, additional, Thibault, Bernard, additional, CADRIN-TOURIGNY, JULIA, additional, Raymond-Paquin, Alexandre, additional, Chabot-Blanchet, Malorie, additional, Fortier, Annik, additional, and Mondesert, Blandine A., additional

Published
2023
Full Text
View/download PDF

6. The Benefits Conferred by Radial Access for Cardiac Catheterization Are Offset by a Paradoxical Increase in the Rate of Vascular Access Site Complications With Femoral Access: The Campeau Radial Paradox

Author

Azzalini, Lorenzo, Tosin, Kunle, Chabot-Blanchet, Malorie, Avram, Robert, Ly, Hung Q., Gaudet, Benoit, Gallo, Richard, Doucet, Serge, Tanguay, Jean-François, Ibrahim, Réda, Grégoire, Jean C., Crépeau, Jacques, Bonan, Raoul, de Guise, Pierre, Nosair, Mohamed, Dorval, Jean-François, Gosselin, Gilbert, L’Allier, Philippe L., Guertin, Marie-Claude, Asgar, Anita W., and Jolicœur, E. Marc

Published
2015
Full Text
View/download PDF

7. Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec

Author

Hassan, Saima, primary, Younan, Rami, additional, Patocskai, Erica, additional, Provencher, Louise, additional, Poirier, Brigitte, additional, Sideris, Luca, additional, Dubé, Pierre, additional, Mihalcioiu, Catalin, additional, Chabot-Blanchet, Malorie, additional, Guertin, Marie-Claude, additional, Boileau, Jean-François, additional, and Robidoux, André, additional

Published
2022
Full Text
View/download PDF

9. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Author

Tardif, Jean-Claude Bouabdallaoui, Nadia L'Allier, Philippe L. and Gaudet, Daniel Shah, Binita Pillinger, Michael H. and Lopez-Sendon, Jose da Luz, Protasio Verret, Lucie Audet, Sylvia Dupuis, Jocelyn Denault, Andre Pelletier, Martin and Tessier, Philippe A. Samson, Sarah Fortin, Denis Tardif, Jean-Daniel Busseuil, David Goulet, Elisabeth Lacoste, Chantal Dubois, Anick Joshi, Avni Y. Waters, David D. and Hsue, Priscilla Lepor, Norman E. Lesage, Frederic Sainturet, Nicolas Roy-Clavel, Eve Bassevitch, Zohar Orfanos, Andreas and Stamatescu, Gabriela Gregoire, Jean C. Busque, Lambert and Lavallee, Christian Hetu, Pierre-Olivier Paquette, Jean-Sebastien Deftereos, Spyridon G. Levesque, Sylvie and Cossette, Marieve Nozza, Anna Chabot-Blanchet, Malorie Dube, Marie-Pierre Guertin, Marie-Claude Boivin, Guy COLCORONA Investigators

Abstract

Background Evidence suggests a role for excessive inflammation in COVID-19 complications. Colchicine is an oral anti-inflammatory medication beneficial in gout, pericarditis, and coronary disease. We aimed to investigate the effect of colchicine on the composite of COVID-19-related death or hospital admission. Methods The present study is a phase 3, randomised, double-blind, adaptive, placebo-controlled, multicentre trial. The study was done in Brazil, Canada, Greece, South Africa, Spain, and the USA, and was led by the Montreal Heart Institute. Patients with COVID-19 diagnosed by PCR testing or clinical criteria who were not being treated in hospital were eligible if they were at least 40 years old and had at least one high-risk characteristic. The randomisation list was computer-generated by an unmasked biostatistician, and masked randomisation was centralised and done electronically through an automated interactive web-response system. The allocation sequence was unstratified and used a 1:1 ratio with a blocking schema and block sizes of six. Patients were randomly assigned to receive orally administered colchicine (0middot5 mg twice per day for 3 days and then once per day for 27 days thereafter) or matching placebo. The primary efficacy endpoint was the composite of death or hospital admission for COVID-19. Vital status at the end of the study was available for 97middot9% of patients. The analyses were done according to the intention-to-treat principle. The COLCORONA trial is registered with ClinicalTrials.gov (NCT04322682) and is now closed to new participants. Findings Trial enrolment began in March 23, 2020, and was completed in Dec 22, 2020. A total of 4488 patients (53middot9% women; median age 54middot0 years, IQR 47middot0-61middot0) were enrolled and 2235 patients were randomly assigned to colchicine and 2253 to placebo. The primary endpoint occurred in 104 (4middot7%) of 2235 patients in the colchicine group and 131 (5middot8%) of 2253 patients in the placebo group (odds ratio [OR] 0middot79, 95middot1% CI 0middot61-1middot03; p=0middot081). Among the 4159 patients with PCR-confirmed COVID-19, the primary endpoint occurred in 96 (4middot6%) of 2075 patients in the colchicine group and 126 (6middot0%) of 2084 patients in the placebo group (OR 0middot75, 0middot57-0middot99; p=0middot042). Serious adverse events were reported in 108 (4middot9%) of 2195 patients in the colchicine group and 139 (6middot3%) of 2217 patients in the placebo group (p=0middot051); pneumonia occurred in 63 (2middot9%) of 2195 patients in the colchicine group and 92 (4middot1%) of 2217 patients in the placebo group (p=0middot021). Diarrhoea was reported in 300 (13middot7%) of 2195 patients in the colchicine group and 161 (7middot3%) of 2217 patients in the placebo group (p

Published
2021

10. Genetics of symptom remission in outpatients with COVID-19

Author

Dubé, Marie-Pierre, primary, Lemaçon, Audrey, additional, Barhdadi, Amina, additional, Perreault, Louis-Philippe Lemieux, additional, Oussaïd, Essaïd, additional, Asselin, Géraldine, additional, Provost, Sylvie, additional, Sun, Maxine, additional, Sandoval, Johanna, additional, Legault, Marc-André, additional, Mongrain, Ian, additional, Dubois, Anick, additional, Valois, Diane, additional, Dedelis, Emma, additional, Lousky, Jennifer, additional, Choi, Julie, additional, Goulet, Elisabeth, additional, Savard, Christiane, additional, Chicoine, Lea-Mei, additional, Cossette, Mariève, additional, Chabot-Blanchet, Malorie, additional, Guertin, Marie-Claude, additional, de Denus, Simon, additional, Bouabdallaoui, Nadia, additional, Marchand, Richard, additional, Bassevitch, Zohar, additional, Nozza, Anna, additional, Gaudet, Daniel, additional, L’Allier, Philippe L, additional, Hussin, Julie, additional, Boivin, Guy, additional, Busseuil, David, additional, and Tardif, Jean-Claude, additional

Published
2021
Full Text
View/download PDF

12. Response to Hjuler et al.

Author

Bissonnette, Robert, primary, Harel, François, additional, Krueger, James G., additional, Guertin, Marie-Claude, additional, Chabot-Blanchet, Malorie, additional, Gonzalez, Juana, additional, Maari, Catherine, additional, Delorme, Isabelle, additional, Lynde, Charles W., additional, and Tardif, Jean-Claude, additional

Published
2017
Full Text
View/download PDF

13. Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome

Author

Gebhard, Catherine, primary, Rhéaume, Eric, additional, Berry, Colin, additional, Brand, Geneviève, additional, Kernaleguen, Anne-Elen, additional, Théberge-Julien, Gabriel, additional, Alam, Mohammad Afaque, additional, Lee, Candace Y. W., additional, Boileau, Laurianne, additional, Chabot-Blanchet, Malorie, additional, Guertin, Marie-Claude, additional, Lavoie, Marc-André, additional, Grégoire, Jean, additional, Ibrahim, Réda, additional, L'Allier, Philippe, additional, and Tardif, Jean-Claude, additional

Published
2017
Full Text
View/download PDF

15. Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34+ Cells in Patients after an Acute Coronary Syndrome.

Author

Gebhard, Catherine, Rhéaume, Eric, Berry, Colin, Brand, Geneviève, Kernaleguen, Anne-Elen, Théberge-Julien, Gabriel, Alam, Mohammad Afaque, Lee, Candace Y. W., Boileau, Laurianne, Chabot-Blanchet, Malorie, Guertin, Marie-Claude, Lavoie, Marc-André, Grégoire, Jean, Ibrahim, Réda, L'Allier, Philippe, and Tardif, Jean-Claude

Subjects
CD34 antigen, HIGH density lipoproteins, ACUTE coronary syndrome, PROGENITOR cells, BLOOD testing, PATIENTS
Abstract

Background: High-density lipoproteins (HDL) favorably affect endothelial progenitor cells (EPC). Circulating progenitor cell level and function are impaired in patients with acute coronary syndrome (ACS). This study investigates the short-term effects of reconstituted HDL (rHDL) on circulating progenitor cells in patients with ACS. Methods and Findings: The study population consisted of 33 patients with recent ACS: 20 patients from the ERASE trial (randomized to receive 4 weekly intravenous infusions of CSL-111 40 mg/kg or placebo) and 13 additional patients recruited as controls using the same enrolment criteria. Blood was collected from 16 rHDL (CSL-111)-treated patients and 17 controls at baseline and at 6–7 weeks (i.e. 2–3 weeks after the fourth infusion of CSL-111 in ERASE). CD34+ and CD34+/kinase insert domain receptor (KDR+) progenitor cell counts were analyzed by flow cytometry. We found preserved CD34+ cell counts in CSL-111-treated subjects at follow-up (change of 1.6%), while the number of CD34+ cells was reduced (-32.9%) in controls (p = 0.017 between groups). The level of circulating SDF-1 (stromal cell-derived factor-1), a chemokine involved in progenitor cell recruitment, increased significantly (change of 21.5%) in controls, while it remained unchanged in CSL-111-treated patients (p = 0.031 between groups). In vitro exposure to CSL-111 of early EPC isolated from healthy volunteers significantly increased CD34+ cells, reduced early EPC apoptosis and enhanced their migration capacity towards SDF-1. Conclusions: The relative increase in circulating CD34+ cells and the low SDF-1 levels observed following rHDL infusions in ACS patients point towards a role of rHDL in cardiovascular repair mechanisms. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

16. Abstract 17913: Inhibition of CETP by Dalcetrapib Results in a Modest Increase in Cholesterol Efflux Capacity Associated With an Increase in Large HDL Particles, but Does Not Impact Carotid Intima-Media Thickness in a dal-PLAQUE-2 Substudy

Author

Rhainds, David, primary, Boule, Marie, additional, Alem, Sonia, additional, Brodeur, Mathieu R, additional, Charpentier, Daniel, additional, Gingras, Olivier, additional, Chabot-Blanchet, Malorie, additional, Guertin, Marie-Claude, additional, Lettre, Guillaume, additional, Rhéaume, Eric, additional, and Tardif, Jean-Claude, additional

Published
2014
Full Text
View/download PDF

17. Changes in Cardiopulmonary Reserve and Peripheral Arterial Function Concomitantly with Subclinical Inflammation and Oxidative Stress in Patients with Heart Failure with Preserved Ejection Fraction

Author

Vitiello, Damien, primary, Harel, François, additional, Touyz, Rhian M., additional, Sirois, Martin G., additional, Lavoie, Joel, additional, Myers, Jonathan, additional, Ducharme, Anique, additional, Racine, Normand, additional, O’Meara, Eileen, additional, Gayda, Mathieu, additional, Chabot-Blanchet, Malorie, additional, Rouleau, Jean Lucien, additional, de Denus, Simon, additional, and White, Michel, additional

Published
2014
Full Text
View/download PDF

19. Abstract 500: Basal Peripheral Arterial Blood Flow Increases Concomitantly with Decreased Cardiopulmonary Reserve and Biomarkers Activation in Patients with Heart Failure and Preserved Ejection Fraction

Author

Vitiello, Damien, primary, Harel, François, additional, Touyz, Rhian M, additional, Sirois, Martin G, additional, Lavoie, Joel, additional, Myers, Jonathan, additional, Gayda, Mathieu, additional, Chabot-Blanchet, Malorie, additional, Rouleau, Jean-Lucien, additional, De Denus, Simon, additional, and White, Michel, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results